Apolipoprotein e, neurodegeneration,and alzheimer disease

JAMA Neurology

Volumn 70, Issue 3, 2013, Pages 299-300

  Jagust, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; GLUCOSE;

ALLELE; ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN METABOLISM; DISEASE ASSOCIATION; EDITORIAL; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE METABOLISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; POSTERIOR CINGULATE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84874835181     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.726     Document Type: Editorial

References (14)

1. Bateman RJ, Xiong C, Benzinger TL, et al Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
2. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825.
3. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122131.
4. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752-758.
5. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(11):6037-6042.
6. Wolk DA, Dickerson BC; Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentionalexecutive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010; 107(22):10256-10261.
7. Protas HD, Chen K, Langbaum JBS, et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease [published online December 3, 2012]. JAMA Neurol. 2013;70(3):320325.
8. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101(1):284-289.
9. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011;10(3):241-252.
10. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103(15):5644-5651.
11. Valla J, Yaari R, Wolf AB, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE 4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis. 2010;22(1):307-313.
12. Sheline YI, Morris JC, Snyder AZ, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF A-42. J Neurosci. 2010;30(50):17035-17040.
13. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1): 119-128.
14. JagustWJ, Mormino EC. Lifespan brain activity,-amyloid, and Alzheimer's disease. Trends Cogn Sci. 2011;15(11):520-526.